Prot #QRK207: A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Project: Research project

StatusActive
Effective start/end date5/5/165/5/22

Funding

  • Parexel (Prot #QRK207)
  • Quark Pharmaceuticals, Inc. (Prot #QRK207)